Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07784036 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT07784036 · ClinicalTrials.gov record · last posted 2026-08-25

JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer

Name: JYP0035 Capsules Plus Fulvestrant in PIK3CA-Mutant HR+/HER2- Advanced Breast Cancer — clinical trial record (NCT07784036)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorChengdu JOYO pharma Co., Ltd.

Started2026-09-30

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of JYP0035 Capsules in Combination With Fulvestrant in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Progressed on Prior Endocrine Therapy

Trial Details

NCT Number	NCT07784036
Lead Sponsor	Chengdu JOYO pharma Co., Ltd.
Conditions	Breast Cancer
Enrollment	171 participants
Start Date	2026-09-30
Primary Completion	2028-11-30 (estimated)
Study Completion	2029-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-25